The effect of PPI use on human gut microbiota and weight loss in patients undergoing laparoscopic Roux-en-Y gastric bypass.
Laparoscopic Roux-en-Y gastric bypass (LRYGB) achieves sustainable weight loss possibly by altering the gut microbiota. The effect of a proton pump inhibitor (PPI) on weight loss and the gut microbiota has not been explored. PPI use and the gut microbiota were assessed before and 6 months after LRYGB in eight patients. Bacterial profiles were generated by 16S ribosomal RNA (rRNA) gene sequencing. Prior to LRYGB, PPI users had a higher percent relative abundance (PRA) of Firmicutes compared to nonusers. PPI users at 6 months post-LRYGB had a higher PRA of Firmicutes [48.6 versus 35.6%, p = nonsignificant (NS)] and a trend toward significantly lower percent excess weight loss (49.3 versus 61.4%, p = 0.067) compared to nonusers. PPI use post-LRYGB may impair weight loss by modifying gut microbiota.
Division of Gastroenterology and Hepatology, University of Colorado Denver, Academic Office Building 1, 12631 East 17th Avenue, Room 7614, MS B158, Aurora, CO, 80045, USA.
Emily K
EK
Ward
Dara P
DP
Schuster
Katie H
KH
Stowers
Amanda K
AK
Royse
Diana
D
Ir
Charles E
CE
Robertson
Daniel N
DN
Frank
Gregory L
GL
Austin
D000328:Adult; D000368:Aged; D041963:Bacteroidetes / Q000235:genetics; D015992:Body Mass Index; D016022:Case-Control Studies; D005260:Female; D015390:Gastric Bypass; D006801:Humans; D007422:Intestines / Q000382:microbiology*; D010535:Laparoscopy; D008297:Male; D064307:Microbiota / Q000235:genetics*; D008875:Middle Aged; D009767:Obesity, Morbid / Q000601:surgery*; D020560:Proteobacteria / Q000235:genetics; D054328:Proton Pump Inhibitors / Q000627:therapeutic use*; D012336:RNA, Ribosomal, 16S / Q000235:genetics*; D016896:Treatment Outcome; D061327:Verrucomicrobia / Q000235:genetics; D015431:Weight Loss; D055815:Young Adult
D054328:Proton Pump Inhibitors; D012336:RNA, Ribosomal, 16S